Trethera
  • Home
  • About Us
  • Technology
  • Pipeline
  • Media
    • News
    • Publications
  • Contact
  • Menu

News

Trethera Doses First Patient in Landmark Clinical Trial for the Treatment of Solid Tumors With First-In-Class Drug TRE-515

14th October 2021/in News /by Trethera

Los Angeles, October 15, 2021— Trethera Corporation (“Trethera”), a biopharmaceutical company committed to developing novel drugs targeting nucleotide metabolism for the treatment of cancer and autoimmune diseases, announced that the first patient has been treated with TRE-515, a first-in-class inhibitor of deoxycytidine kinase (dCK). Trethera’s multi-site Phase 1 study will evaluate TRE-515 monotherapy in up […]

Read more
https://www.trethera.com/wp-content/uploads/2015/12/trethera_logo-wo.png 0 0 Trethera https://www.trethera.com/wp-content/uploads/2015/12/trethera_logo-wo.png Trethera2021-10-14 23:44:052021-12-14 16:52:59Trethera Doses First Patient in Landmark Clinical Trial for the Treatment of Solid Tumors With First-In-Class Drug TRE-515

Globally Recognized Multiple Sclerosis Expert, Dr. Lawrence “Larry” Steinman, Joins Trethera Scientific Advisory Board

25th May 2021/in News /by Trethera

Los Angeles, May 25, 2021 – Trethera Corporation (Trethera), a biopharmaceutical company committed to developing novel drugs targeting cellular nucleotide metabolism for the treatment of cancers and autoimmune diseases, is pleased to announce the appointment of renowned autoimmunity researcher Dr. Larry Steinman to its Scientific Advisory Board.  Dr. Steinman will be advising Trethera regarding TRE-515 development, a first-in-class compound with the potential to treat multiple sclerosis (MS) and other autoimmune neurologic diseases. […]

Read more
https://www.trethera.com/wp-content/uploads/2015/12/trethera_logo-wo.png 0 0 Trethera https://www.trethera.com/wp-content/uploads/2015/12/trethera_logo-wo.png Trethera2021-05-25 00:25:002021-12-14 17:04:27Globally Recognized Multiple Sclerosis Expert, Dr. Lawrence “Larry” Steinman, Joins Trethera Scientific Advisory Board

Trethera Receives FDA Approval To Initiate TRE-515 Phase 1 Clinical Trial in Solid Tumors Monotherapy

19th April 2021/in News /by Trethera

Los Angeles, April 19, 2021— Trethera Corporation (Trethera), a biopharmaceutical company committed to developing novel drugs targeting cellular nucleotide metabolism for the treatment of cancer and autoimmune diseases, announced that the U.S. Food and Drug Administration (FDA) has approved its TRE-515 investigational new drug (IND) application for the treatment of solid tumor malignancies.  Trethera will […]

Read more
https://www.trethera.com/wp-content/uploads/2015/12/trethera_logo-wo.png 0 0 Trethera https://www.trethera.com/wp-content/uploads/2015/12/trethera_logo-wo.png Trethera2021-04-19 00:22:002021-05-26 00:59:43Trethera Receives FDA Approval To Initiate TRE-515 Phase 1 Clinical Trial in Solid Tumors Monotherapy

Trethera Announces Jefferies & Company Chairman Emeritus Frank Baxter as Special Advisor

16th March 2021/in News /by Trethera

Los Angeles, March 16, 2021— Trethera Corporation (“Trethera”), a biopharmaceutical company committed to developing novel drugs targeting cellular nucleotide metabolism for the treatment of cancer and autoimmune diseases announces that Frank Baxter has been appointed as special advisor. He will be advising Trethera and its board of directors on financing options including private equity, public […]

Read more
https://www.trethera.com/wp-content/uploads/2015/12/trethera_logo-wo.png 0 0 Trethera https://www.trethera.com/wp-content/uploads/2015/12/trethera_logo-wo.png Trethera2021-03-16 16:50:462021-03-16 16:52:33Trethera Announces Jefferies & Company Chairman Emeritus Frank Baxter as Special Advisor

Trethera Announces Completion of $3.2 Million Seed Funding Round From Current Investors

24th February 2021/in News /by Trethera

Los Angeles, February 24, 2021— Trethera Corporation (“Trethera”), a biopharmaceutical company committed to developing novel drugs targeting cellular nucleotide metabolism for the treatment of cancer and autoimmune diseases, is pleased to announce completion of its Seed Preferred 3 Stock financing.  Trethera raised an aggregate of $3.2 million from its existing investors, which funds will be […]

Read more
https://www.trethera.com/wp-content/uploads/2015/12/trethera_logo-wo.png 0 0 Trethera https://www.trethera.com/wp-content/uploads/2015/12/trethera_logo-wo.png Trethera2021-02-24 03:50:002021-03-08 18:05:11Trethera Announces Completion of $3.2 Million Seed Funding Round From Current Investors
Page 4 of 512345